Stanford researchers found that a single dose of ibogaine may dramatically reduce PTSD and TBI symptoms in veterans—offering ...

Psyence Biomedical Ltd. (NASDAQ: PBM) ("Psyence BioMed" or the "Company") today announced a strategic follow-on investment of ...

Ibogaine, a naturally occurring psychoactive substance derived from the Tabernanthe iboga plant, has shown promise in early-stage research for its unique ability to interrupt SUDs, offering a ...

Psyence Biomedical (NASDAQ: PBM) invested an additional $500,000 in PsyLabs, deepening its relationship with the psychedelic ingredients producer while securing exclusive access to ...

COLUMBUS, Ohio, April 16, 2025 /PRNewswire-PRWeb/ -- The Ohio State University's Center for Psychedelic Drug Research and Education (CPDRE) has launched the Global Ibogaine Patient Survey, the ...